Table 5.
Univariate and multivariate analysis of factors contributing to SVR24 (telaprevir)
| Factors |
Univariate analysis |
Multivariate analysis |
||
| Odds ratio (95%CI) | P value | Odds ratio (95%CI) | P value | |
| Age | 1.012 (0.955-1.072) | 0.689 | ||
| Gender (female) | 0.784 (0.262-2.342) | 0.663 | ||
| Body mass index (kg/m2) | 1.074 (0.875-1.318) | 0.495 | ||
| Prior treatment response (non-NR) | 3.850 (0.830-17.861) | 0.085 | ||
| Baseline HCV-RNA (log IU/mL) | 1.264 (0.457-3.495) | 0.652 | ||
| Baseline ALT (IU/mL) | 1.008 (0.998-1.017) | 0.105 | ||
| Baseline platelets (× 104/mm3) | 1.017 (0.906-1.142) | 0.775 | ||
| Baseline hemoglobin (g/dL) | 1.038 (0.736-1.464) | 0.830 | ||
| IL28B SNP (TT) | 6.700 (1.826-24.584) | 0.004 | 8.160 (1.593-41.804) | 0.012 |
| Initial dose of TVR (2250 mg/d) | 2.069 (0.670-6.553) | 0.204 | ||
| TVR/BW (mg/kg per day) | 0.938 (0.870-1.011) | 0.093 | ||
| RBV/BW (mg/kg per day) | 0.811 (0.617-1.066) | 0.133 | ||
| PEG-IFN dose reduction (none) | 2.134 (0.253-17.988) | 0.486 | ||
| TVR dose reduction (none) | 1.020 (0.281-3.703) | 0.976 | ||
| RBV dose reduction (none) | 1.548 (0.433-5.525) | 0.501 | ||
| Adherence of RBV (> 60%) | 6.873 (1.784-26.474) | 0.005 | 11.052 (1.160-105.273) | 0.037 |
| RVR (none) | 0.88 (0.123-1.216) | 0.104 | ||
HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NR: Non-responder; IL28B SNP: Interleukin-28B single nucleotide polymorphism; TVR: Telaprevir; RVR: Rapid virological response; PEG-IFN: Pegylated interferon; BW: Bodyweight; RBV: Ribavirin.